{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:14:06Z","timestamp":1789330446749,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Iron deficiency (ID) is the most common nutritional disorder worldwide. It is often observed in patients with chronic diseases, such as heart failure (HF), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and cancer. ID is associated with poor clinical outcome, including poor performance, reduced quality of life, as well as increased hospitalization and mortality. The aim of this review is to provide an overview about the role of ID in chronic diseases (HF, CKD, IBD, cancer) regarding their current definitions and clinical relevance; diagnostic accuracy of iron parameters in chronic inflammatory conditions and its potential as prognostic markers. Due to different definitions and guideline recommendations of ID, various laboratory parameters for ID diagnostic exist and there is no general consensus about the definition of ID and its treatment. Still, a general trend can be observed across all investigated indications of this review (HF, CKD, IBD, cancer) that serum ferritin and transferrin saturation (TSAT) are the two parameters mentioned most often and emphasized in all guidelines to define ID and guide treatment. The most commonly used threshold values for the diagnosis of ID are TSAT of\u2009&lt;\u200920% and serum ferritin of\u2009&lt;\u2009100\u2013300\u00a0\u00b5g\/L. Noteworthy, both TSAT and particularly ferritin are frequently applied, but both may vary due to inflammatory conditions. Studies showed that TSAT is less affected by inflammatory processes and may therefore be more accurate and reliable than serum ferritin, particularly in conditions with elevated inflammatory state. A low iron status and particularly a low TSAT value was associated with a poor outcome in all investigated indications, with the strongest evidence in HF patients. Routine surveillance of iron status in these groups of patients with chronic conditions is advisable to detect ID early. Depending on the inflammatory state, TSAT\u2009&lt;\u200920% may be the more accurate diagnostic marker of ID than ferritin. Moreover, TSAT may also be the more reliable estimate for the prognosis, particularly in HF.<\/jats:p>","DOI":"10.1186\/s40001-022-00922-6","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:11:02Z","timestamp":1673237462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4729-8495","authenticated-orcid":false,"given":"Martina","family":"Rohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"922_CR1","unstructured":"Organization WH. Micronutrient deficiencies 2020. https:\/\/www.who.int\/nutrition\/topics\/ida\/en\/. Accessed 10 June 2020."},{"issue":"8","key":"922_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/10408363.2019.1653820","volume":"56","author":"P Cacoub","year":"2019","unstructured":"Cacoub P, Vandewalle C, Peoc\u2019h K. Using transferrin saturation as a diagnostic criterion for iron deficiency: a systematic review. Crit Rev Clin Lab Sci. 2019;56(8):526\u201332. https:\/\/doi.org\/10.1080\/10408363.2019.1653820.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"922_CR3","first-page":"104","volume":"26","author":"J Stein","year":"2013","unstructured":"Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease \u2013 a practical approach. Ann Gastroenterol. 2013;26(2):104\u201313.","journal-title":"Ann Gastroenterol"},{"issue":"10","key":"922_CR4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/ajh.24820","volume":"92","author":"MD Cappellini","year":"2017","unstructured":"Cappellini MD, Comin-Colet J, de Francisco A, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92(10):1068\u201378. https:\/\/doi.org\/10.1002\/ajh.24820.","journal-title":"Am J Hematol"},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"9394060","DOI":"10.1155\/2018\/9394060","volume":"2018","author":"A Dignass","year":"2018","unstructured":"Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. Int J Chronic Dis. 2018;2018:9394060. https:\/\/doi.org\/10.1155\/2018\/9394060.","journal-title":"Int J Chronic Dis."},{"issue":"7","key":"922_CR6","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","volume":"24","author":"H Ludwig","year":"2013","unstructured":"Ludwig H, M\u00fcld\u00fcr E, Endler G, H\u00fcbl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24(7):1886\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdt118.","journal-title":"Ann Oncol"},{"issue":"2","key":"922_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","volume":"73","author":"P Martens","year":"2018","unstructured":"Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018;73(2):115\u201323. https:\/\/doi.org\/10.1080\/00015385.2017.1351239.","journal-title":"Acta Cardiol"},{"issue":"4","key":"922_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","volume":"165","author":"IT Klip","year":"2013","unstructured":"Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-82.e3. https:\/\/doi.org\/10.1016\/j.ahj.2013.01.017.","journal-title":"Am Heart J"},{"issue":"1","key":"922_CR9","doi-asserted-by":"publisher","first-page":"e0191541","DOI":"10.1371\/journal.pone.0191541","volume":"13","author":"M Aoun","year":"2018","unstructured":"Aoun M, Karam R, Sleilaty G, Antoun L, Ammar W. Iron deficiency across chronic kidney disease stages: is there a reverse gender pattern? PLoS ONE. 2018;13(1):e0191541. https:\/\/doi.org\/10.1371\/journal.pone.0191541.","journal-title":"PLoS ONE"},{"issue":"3","key":"922_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/sj.ki.5000105","volume":"69","author":"CP Kovesdy","year":"2006","unstructured":"Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69(3):560\u20134. https:\/\/doi.org\/10.1038\/sj.ki.5000105.","journal-title":"Kidney Int"},{"key":"922_CR11","unstructured":"Hastka J, Metzgeroth G, Gattermann N. Onkopedia Leitlinien. Eisenmangel und Eisenmangelan\u00e4mie 2022. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/eisenmangel-und-eisenmangelanaemie\/@@guideline\/html\/index.html. Accessed 30 Aug 2022."},{"issue":"36","key":"922_CR12","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","volume":"35","author":"EA Jankowska","year":"2014","unstructured":"Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35(36):2468\u201376. https:\/\/doi.org\/10.1093\/eurheartj\/ehu235.","journal-title":"Eur Heart J"},{"issue":"1","key":"922_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","volume":"142","author":"MW Hentze","year":"2010","unstructured":"Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24\u201338. https:\/\/doi.org\/10.1016\/j.cell.2010.06.028.","journal-title":"Cell"},{"key":"922_CR14","volume-title":"Iron therapy in renal anaemia","author":"G Mircescu","year":"2013","unstructured":"Mircescu G, Crichton R, Geisser P. Iron therapy in renal anaemia. Bremen: UNI-MED Verlag AG; 2013."},{"issue":"2","key":"922_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/joim.13004","volume":"287","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153\u201370. https:\/\/doi.org\/10.1111\/joim.13004.","journal-title":"J Intern Med"},{"key":"922_CR16","doi-asserted-by":"crossref","unstructured":"Metzgeroth G, Hastka J. Diagnostic work-up of iron deficiency\/Diagnostisches Vorgehen bei Eisenmangel. 2004.","DOI":"10.1515\/LabMed.2004.054"},{"issue":"5","key":"922_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/10408363.2015.1038744","volume":"52","author":"NM Archer","year":"2015","unstructured":"Archer NM, Brugnara C. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci. 2015;52(5):256\u201372. https:\/\/doi.org\/10.3109\/10408363.2015.1038744.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"922_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.acc.2016.03.002","volume":"75","author":"ME Elsayed","year":"2016","unstructured":"Elsayed ME, Sharif MU, Stack AG. Transferrin saturation: a body iron biomarker. Adv Clin Chem. 2016;75:71\u201397. https:\/\/doi.org\/10.1016\/bs.acc.2016.03.002.","journal-title":"Adv Clin Chem"},{"issue":"Suppl 1","key":"922_CR19","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2215\/CJN.01490506","volume":"1","author":"JB Wish","year":"2006","unstructured":"Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl 1):S4-8. https:\/\/doi.org\/10.2215\/CJN.01490506.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 4","key":"922_CR20","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","volume":"29","author":"M Aapro","year":"2018","unstructured":"Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv96\u2013110. https:\/\/doi.org\/10.1093\/annonc\/mdx758.","journal-title":"Ann Oncol"},{"issue":"3","key":"922_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","volume":"9","author":"AU Dignass","year":"2015","unstructured":"Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju009.","journal-title":"J Crohns Colitis"},{"key":"922_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.4","author":"KDIGO","year":"2012","unstructured":"KDIGO. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Official J Int Society Nephrol. 2012. https:\/\/doi.org\/10.1038\/kisup.2012.4.","journal-title":"Official J Int Society Nephrol"},{"key":"922_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"2","key":"922_CR24","doi-asserted-by":"publisher","first-page":"e004519","DOI":"10.1161\/circheartfailure.117.004519","volume":"11","author":"N Grote Beverborg","year":"2018","unstructured":"Grote Beverborg N, Klip IT, Meijers WC, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11(2):e004519. https:\/\/doi.org\/10.1161\/circheartfailure.117.004519.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"922_CR25","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3945\/ajcn.114.103366","volume":"102","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585\u201394. https:\/\/doi.org\/10.3945\/ajcn.114.103366.","journal-title":"Am J Clin Nutr"},{"issue":"23","key":"922_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.V126.23.955.955","volume":"126","author":"JC Ho","year":"2015","unstructured":"Ho JC, Stevic I, Chan A, Lau KK, Chan HHW. Serum ferritin is not sensitive or specific for the diagnosis of iron deficiency in patients with normocytic anemia. Blood. 2015;126(23):955. https:\/\/doi.org\/10.1182\/blood.V126.23.955.955.","journal-title":"Blood"},{"issue":"3","key":"922_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000014542","volume":"7","author":"CN Lok","year":"1998","unstructured":"Lok CN, Loh TT. Regulation of transferrin function and expression: review and update. Biol Signals Recept. 1998;7(3):157\u201378. https:\/\/doi.org\/10.1159\/000014542.","journal-title":"Biol Signals Recept"},{"issue":"7","key":"922_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/clinchem\/48.7.1066","volume":"48","author":"C Thomas","year":"2002","unstructured":"Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48(7):1066\u201376.","journal-title":"Clin Chem"},{"issue":"12","key":"922_CR29","doi-asserted-by":"publisher","first-page":"E158","DOI":"10.1002\/ibd.21881","volume":"17","author":"P Oustamanolakis","year":"2011","unstructured":"Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis. 2011;17(12):E158\u20139. https:\/\/doi.org\/10.1002\/ibd.21881.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"922_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the heart failure Society of America. J Am Coll Cardiol. 2017;70(6):776\u2013803. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"922_CR31","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2012.270","volume":"82","author":"TB Dr\u00fceke","year":"2012","unstructured":"Dr\u00fceke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82(9):952\u201360. https:\/\/doi.org\/10.1038\/ki.2012.270.","journal-title":"Kidney Int"},{"issue":"5","key":"922_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","volume":"62","author":"AS Kliger","year":"2013","unstructured":"Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62(5):849\u201359. https:\/\/doi.org\/10.1053\/j.ajkd.2013.06.008.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"922_CR33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, B\u00e1r\u00e1ny P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346\u201359. https:\/\/doi.org\/10.1093\/ndt\/gft033.","journal-title":"Nephrol Dial Transplant"},{"key":"922_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management. NICE guideline (NG203). Published: 25 August 2021. Last updated: 24 Nov 2021. https:\/\/www.nice.org.uk\/guidance\/ng203. Accessed 10 Sept 2022."},{"issue":"1","key":"922_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, et al. 2015 Japanese Society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. Renal Replacement Therapy. 2017;3(1):36. https:\/\/doi.org\/10.1186\/s41100-017-0114-y.","journal-title":"Renal Replacement Therapy"},{"issue":"11","key":"922_CR36","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","volume":"70","author":"J Snook","year":"2021","unstructured":"Snook J, Bhala N, Beales ILP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030\u201351. https:\/\/doi.org\/10.1136\/gutjnl-2021-325210.","journal-title":"Gut"},{"key":"922_CR37","unstructured":"Griffiths E, Roy V, Alwan L, al. Ne. NCCN Guidelines Version 1.2022. Hematopoietic Growth Faktors. Management of Cancer- and Chemotherapy-Induced Anemia: National Comprehensive Cancer Network (NCCN); 2021. Version 1.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed 30 Aug 2022."},{"key":"922_CR38","first-page":"2020","volume-title":"WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations","author":"World Health O","year":"2020","unstructured":"World Health O. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. p. 2020."},{"issue":"2","key":"922_CR39","first-page":"98","volume":"87","author":"MW Short","year":"2013","unstructured":"Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87(2):98\u2013104.","journal-title":"Am Fam Physician"},{"key":"922_CR40","unstructured":"BCGuidelines.ca. Iron Deficiency \u2013 Diagnosis and Management: British Columbia; 2019. https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/practitioner-pro\/bc-guidelines\/iron-deficiency.pdf. Accessed 8 May 2021."},{"issue":"3","key":"922_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.236","volume":"17","author":"T McDonagh","year":"2015","unstructured":"McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Failure. 2015;17(3):248\u201362. https:\/\/doi.org\/10.1002\/ejhf.236.","journal-title":"Eur J Heart Failure."},{"issue":"8","key":"922_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2008.10.046","volume":"53","author":"A Kazory","year":"2009","unstructured":"Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol. 2009;53(8):639\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.046.","journal-title":"J Am Coll Cardiol"},{"key":"922_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55070329","author":"O Sirbu","year":"2019","unstructured":"Sirbu O, Sorodoc V, Jaba IM, et al. The influence of cardiovascular medications on iron metabolism in patients with heart failure. Medicina (Kaunas). 2019. https:\/\/doi.org\/10.3390\/medicina55070329.","journal-title":"Medicina (Kaunas)"},{"issue":"9","key":"922_CR44","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1172\/jci119769","volume":"100","author":"M Mrug","year":"1997","unstructured":"Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100(9):2310\u20134. https:\/\/doi.org\/10.1172\/jci119769.","journal-title":"J Clin Invest"},{"issue":"9","key":"922_CR45","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","volume":"36","author":"M Guedes","year":"2021","unstructured":"Guedes M, Muenz D, Zee J, et al. Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrol Dial Transplant. 2021;36(9):1694\u2013703. https:\/\/doi.org\/10.1093\/ndt\/gfab050.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"922_CR46","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","volume":"112","author":"PVD Meer","year":"2005","unstructured":"Meer PVD, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially explain the occurrence of anemia in heart failure. Circulation. 2005;112(12):1743\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.549121.","journal-title":"Circulation"},{"issue":"3","key":"922_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40256-016-0211-2","volume":"17","author":"M Drozd","year":"2017","unstructured":"Drozd M, Jankowska EA, Banasiak W, Ponikowski P. Iron therapy in patients with heart failure and iron deficiency: review of iron preparations for practitioners. Am J Cardiovasc Drugs. 2017;17(3):183\u2013201. https:\/\/doi.org\/10.1007\/s40256-016-0211-2.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"10","key":"922_CR48","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/s-0043-100900","volume":"142","author":"W Doehner","year":"2017","unstructured":"Doehner W, Blankenberg S, Erdmann E, et al. Iron deficiency in chronic heart failure: diagnostic algorithm and present-day therapeutic options. Dtsch Med Wochenschr. 2017;142(10):752\u20137. https:\/\/doi.org\/10.1055\/s-0043-100900.","journal-title":"Dtsch Med Wochenschr"},{"issue":"11","key":"922_CR49","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","volume":"17","author":"EA Jankowska","year":"2011","unstructured":"Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17(11):899\u2013906. https:\/\/doi.org\/10.1016\/j.cardfail.2011.08.003.","journal-title":"J Card Fail"},{"issue":"10","key":"922_CR50","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/eurjhf\/hft083","volume":"15","author":"J Comin-Colet","year":"2013","unstructured":"Comin-Colet J, Enjuanes C, Gonzalez G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15(10):1164\u201372. https:\/\/doi.org\/10.1093\/eurjhf\/hft083.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"922_CR51","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamacardio.2019.1739","volume":"4","author":"N Grote Beverborg","year":"2019","unstructured":"Grote Beverborg N, van der Wal HH, Klip IT, et al. Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF Studies. JAMA Cardiol. 2019;4(7):696\u2013701. https:\/\/doi.org\/10.1001\/jamacardio.2019.1739.","journal-title":"JAMA Cardiol."},{"key":"922_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijcard.2017.04.110","volume":"243","author":"P Moliner","year":"2017","unstructured":"Moliner P, Jankowska EA, van Veldhuisen DJ, et al. Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. Int J Cardiol. 2017;243:360\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2017.04.110.","journal-title":"Int J Cardiol"},{"key":"922_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041199","author":"A Alcaide-Aldeano","year":"2020","unstructured":"Alcaide-Aldeano A, Garay A, Alcoberro L, et al. Iron deficiency: impact on functional capacity and quality of life in heart failure with preserved ejection fraction. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9041199.","journal-title":"J Clin Med"},{"key":"922_CR54","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.297242","author":"T Grammer","year":"2019","unstructured":"Grammer T, Scharnagl H, Dressel A, et al. Iron Metabolism, hepcidin, and mortality (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chemis. 2019. https:\/\/doi.org\/10.1373\/clinchem.2018.297242.","journal-title":"Clin Chemis."},{"key":"922_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijcard.2020.03.020","volume":"309","author":"AP Ambrosy","year":"2020","unstructured":"Ambrosy AP, Fitzpatrick JK, Tabada GH, et al. A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. Int J Cardiol. 2020;309:95\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2020.03.020.","journal-title":"Int J Cardiol"},{"issue":"7","key":"922_CR56","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/ejhf.513","volume":"18","author":"J N\u00fa\u00f1ez","year":"2016","unstructured":"N\u00fa\u00f1ez J, Com\u00edn-Colet J, Mi\u00f1ana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18(7):798\u2013802. https:\/\/doi.org\/10.1002\/ejhf.513.","journal-title":"Eur J Heart Fail"},{"key":"922_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13617","author":"S Fitzsimons","year":"2021","unstructured":"Fitzsimons S, Yeo TJ, Ling L, et al. Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Failure. 2021. https:\/\/doi.org\/10.1002\/ehf2.13617.","journal-title":"ESC Heart Failure."},{"key":"922_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa112","author":"J Campodonico","year":"2021","unstructured":"Campodonico J, Nicoli F, Motta I, et al. Prognostic role of transferrin saturation in heart failure patients. Eur J Prev Cardiol. 2021. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa112.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"922_CR59","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/eurjhf\/hft083","volume":"15","author":"J Com\u00edn-Colet","year":"2013","unstructured":"Com\u00edn-Colet J, Enjuanes C, Gonz\u00e1lez G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15(10):1164\u201372. https:\/\/doi.org\/10.1093\/eurjhf\/hft083.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"922_CR60","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/eurjhf\/hfp140","volume":"11","author":"SD Anker","year":"2009","unstructured":"Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail. 2009;11(11):1084\u201391. https:\/\/doi.org\/10.1093\/eurjhf\/hfp140.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"922_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ehf2.12006","volume":"1","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Fail. 2014;1(1):52\u20138. https:\/\/doi.org\/10.1002\/ehf2.12006.","journal-title":"ESC Heart Fail."},{"issue":"1","key":"922_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125\u201333. https:\/\/doi.org\/10.1002\/ejhf.823.","journal-title":"Eur J Heart Fail"},{"issue":"10266","key":"922_CR63","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan B-A, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. 2020;396(10266):1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4.","journal-title":"The Lancet"},{"key":"922_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab234","author":"EA Jankowska","year":"2021","unstructured":"Jankowska EA, Kirwan B-A, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab234.","journal-title":"Eur Heart J"},{"issue":"6","key":"922_CR65","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2021.07.013","volume":"100","author":"RC Mehta","year":"2021","unstructured":"Mehta RC, Cho ME, Cai X, et al. Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int. 2021;100(6):1292\u2013302. https:\/\/doi.org\/10.1016\/j.kint.2021.07.013.","journal-title":"Kidney Int"},{"issue":"3","key":"922_CR66","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2019.04.029","volume":"96","author":"ME Cho","year":"2019","unstructured":"Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int. 2019;96(3):750\u201360. https:\/\/doi.org\/10.1016\/j.kint.2019.04.029.","journal-title":"Kidney Int"},{"key":"922_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz192","author":"AA Awan","year":"2019","unstructured":"Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2019. https:\/\/doi.org\/10.1093\/ndt\/gfz192.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"922_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000499758","volume":"48","author":"M Sato","year":"2019","unstructured":"Sato M, Hanafusa N, Tsuchiya K, Kawaguchi H, Nitta K. Impact of transferrin saturation on all-cause mortality in patients on maintenance hemodialysis. Blood Purif. 2019;48(2):158\u201366. https:\/\/doi.org\/10.1159\/000499758.","journal-title":"Blood Purif"},{"issue":"1","key":"922_CR69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2369-10-6","volume":"10","author":"VE Pollak","year":"2009","unstructured":"Pollak VE, Lorch JA, Shukla R, Satwah S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol. 2009;10(1):6. https:\/\/doi.org\/10.1186\/1471-2369-10-6.","journal-title":"BMC Nephrol"},{"issue":"4","key":"922_CR70","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1053\/j.ajkd.2003.12.029","volume":"43","author":"K Kalantar-Zadeh","year":"2004","unstructured":"Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis. 2004;43(4):671\u201384. https:\/\/doi.org\/10.1053\/j.ajkd.2003.12.029.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"922_CR71","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/j.jrn.2018.11.004","volume":"29","author":"SC Yeh","year":"2019","unstructured":"Yeh SC, Lin YC, Hong YC, Hsu CC, Lin YC, Wu MS. Different effects of iron indices on mortality in patients with autosomal dominant polycystic kidney disease after long-term hemodialysis: a nationwide population-based study. J Ren Nutr. 2019;29(5):444\u201353. https:\/\/doi.org\/10.1053\/j.jrn.2018.11.004.","journal-title":"J Ren Nutr"},{"issue":"2","key":"922_CR72","doi-asserted-by":"publisher","first-page":"e87231","DOI":"10.1371\/journal.pone.0087231","volume":"9","author":"HM Koo","year":"2014","unstructured":"Koo HM, Kim CH, Doh FM, et al. The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS ONE. 2014;9(2):e87231. https:\/\/doi.org\/10.1371\/journal.pone.0087231.","journal-title":"PLoS ONE"},{"issue":"1","key":"922_CR73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","volume":"19","author":"MF Eisenga","year":"2018","unstructured":"Eisenga MF, Nolte IM, van der Meer P, Bakker SJL, Gaillard C. Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrol. 2018;19(1):225. https:\/\/doi.org\/10.1186\/s12882-018-1021-3.","journal-title":"BMC Nephrol"},{"issue":"1","key":"922_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/hdi.12078","volume":"18","author":"AE Gaweda","year":"2014","unstructured":"Gaweda AE, Bhat P, Maglinte GA, et al. TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients. Hemodial Int. 2014;18(1):38\u201346. https:\/\/doi.org\/10.1111\/hdi.12078.","journal-title":"Hemodial Int"},{"issue":"3","key":"922_CR75","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1046\/j.1523-1755.2003.00826.x","volume":"63","author":"Y Kaneko","year":"2003","unstructured":"Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int. 2003;63(3):1086\u201393. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00826.x.","journal-title":"Kidney Int"},{"issue":"1","key":"922_CR76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/kisup.2015.6","volume":"5","author":"T Hamano","year":"2015","unstructured":"Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl. 2015;5(1):23\u201332. https:\/\/doi.org\/10.1038\/kisup.2015.6.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"922_CR77","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4103\/0971-4065.57105","volume":"19","author":"S Gupta","year":"2009","unstructured":"Gupta S, Uppal B, Pawar B. Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients? Indian J Nephrol. 2009;19(3):96\u2013100. https:\/\/doi.org\/10.4103\/0971-4065.57105.","journal-title":"Indian J Nephrol."},{"issue":"4","key":"922_CR78","doi-asserted-by":"publisher","first-page":"248","DOI":"10.4103\/ijn.IJN_159_18","volume":"29","author":"M Venkatesan","year":"2019","unstructured":"Venkatesan M, Saxena S, Kumar A. Evaluation of iron status in patients of chronic kidney disease\u2014a study to assess the best indicators including serum transferrin receptor assay. Indian J Nephrol. 2019;29(4):248\u201353. https:\/\/doi.org\/10.4103\/ijn.IJN_159_18.","journal-title":"Indian J Nephrol"},{"issue":"11\u201312","key":"922_CR79","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1365-2036.2006.03146.x","volume":"24","author":"S Kulnigg","year":"2006","unstructured":"Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn\u2019s disease. Aliment Pharmacol Ther. 2006;24(11\u201312):1507\u201323. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03146.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"922_CR80","doi-asserted-by":"publisher","first-page":"582163","DOI":"10.1155\/2015\/582163","volume":"2015","author":"C \u00c7eki\u00e7","year":"2015","unstructured":"\u00c7eki\u00e7 C, \u0130pek S, Aslan F, et al. The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency. Gastroenterol Res Pract. 2015;2015:582163. https:\/\/doi.org\/10.1155\/2015\/582163.","journal-title":"Gastroenterol Res Pract."},{"issue":"8","key":"922_CR81","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/annonc\/mds112","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, \u00d6sterborg A, Gasc\u00f3n P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23(8):1954\u201362. https:\/\/doi.org\/10.1093\/annonc\/mds112.","journal-title":"Ann Oncol"},{"key":"922_CR82","doi-asserted-by":"publisher","first-page":"8057650","DOI":"10.1155\/2016\/8057650","volume":"2016","author":"T Steinmetz","year":"2016","unstructured":"Steinmetz T, Schr\u00f6der J, Plath M, et al. Antianemic treatment of cancer patients in German routine practice: data from a prospective cohort study-the tumor anemia registry. Anemia. 2016;2016:8057650. https:\/\/doi.org\/10.1155\/2016\/8057650.","journal-title":"Anemia."},{"issue":"4","key":"922_CR83","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00520-019-04938-3","volume":"28","author":"A Saint","year":"2020","unstructured":"Saint A, Viotti J, Borchiellini D, et al. Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. Support Care Cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2020;28(4):1639\u201347. https:\/\/doi.org\/10.1007\/s00520-019-04938-3.","journal-title":"Support Care Cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"9","key":"922_CR84","doi-asserted-by":"publisher","first-page":"e0163817","DOI":"10.1371\/journal.pone.0163817","volume":"11","author":"G Kanuri","year":"2016","unstructured":"Kanuri G, Sawhney R, Varghese J, Britto M, Shet A. Iron deficiency anemia coexists with cancer related anemia and adversely impacts quality of life. PLoS ONE. 2016;11(9):e0163817. https:\/\/doi.org\/10.1371\/journal.pone.0163817.","journal-title":"PLoS ONE"},{"issue":"10","key":"922_CR85","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1007\/s00520-016-3258-3","volume":"24","author":"L Family","year":"2016","unstructured":"Family L, Xu L, Xu H, et al. The effect of chemotherapy-induced anemia on dose reduction and dose delay. Support Care Cancer. 2016;24(10):4263\u201371. https:\/\/doi.org\/10.1007\/s00520-016-3258-3.","journal-title":"Support Care Cancer"},{"key":"922_CR86","doi-asserted-by":"publisher","first-page":"635899","DOI":"10.3389\/fimmu.2021.635899","volume":"12","author":"A Aksan","year":"2021","unstructured":"Aksan A, Farrag K, Aksan S, Schroeder O, Stein J. Flipside of the coin: iron deficiency and colorectal cancer. Front Immunol. 2021;12:635899. https:\/\/doi.org\/10.3389\/fimmu.2021.635899.","journal-title":"Front Immunol"},{"issue":"11","key":"922_CR87","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh S, Hutter G, Spitler R, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11(11):986\u201394. https:\/\/doi.org\/10.1038\/nnano.2016.168.","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"922_CR88","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/annonc\/mds338","volume":"24","author":"T Steinmetz","year":"2013","unstructured":"Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475\u201382. https:\/\/doi.org\/10.1093\/annonc\/mds338.","journal-title":"Ann Oncol"},{"issue":"3","key":"922_CR89","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00384-015-2461-x","volume":"31","author":"JL Calleja","year":"2016","unstructured":"Calleja JL, Delgado S, del Val A, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis. 2016;31(3):543\u201351. https:\/\/doi.org\/10.1007\/s00384-015-2461-x.","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"922_CR90","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/anae.14659","volume":"74","author":"BD Keeler","year":"2019","unstructured":"Keeler BD, Dickson EA, Simpson JA, et al. The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial. Anaesthesia. 2019;74(6):714\u201325. https:\/\/doi.org\/10.1111\/anae.14659.","journal-title":"Anaesthesia"},{"issue":"4","key":"922_CR91","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s0002-9343(02)01214-7","volume":"113","author":"GN Ioannou","year":"2002","unstructured":"Ioannou GN, Rockey DC, Bryson CL, Weiss NS. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002;113(4):276\u201380. https:\/\/doi.org\/10.1016\/s0002-9343(02)01214-7.","journal-title":"Am J Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00922-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T08:03:27Z","timestamp":1673510607000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00922-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00922-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no ethics approval necessary because this is a review of the literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Martina Rohr is employed at Vifor Pharma. Vincent Brandenburg received lecture fees from Vifor Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}